![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Active Filter(s):
Details:
The acquisition provides Ariceum with an expanded portfolio of therapeutic and diagnostic assets including, AT-001, a I-123-labelled PARP inhibitor for the treatment of aggressively growing cancers and it has UK ILAP approval for primary and recurrent glioblastoma.
Lead Product(s): ATD-001
Therapeutic Area: Oncology Product Name: ATD-001
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Ariceum Therapeutics
Deal Size: $44 million Upfront Cash: $2.5 million
Deal Type: Acquisition June 01, 2023